CEO Message – Biojo Sciences

Brandon Jurado, MBA

As Senior VP of Operations at Biojo, Brandon Jurado has over 20 years of diversified experience. He recently spent over eight years in the biopharmaceutical industry as the Director of Strategy & Business Development and Manager of Global Business Development at Mocuis, Co., Ltd., a biopharmaceutical advisory and investment firm. Mr. Jurado collaborated with business, scientific, regulatory, and investor teams in developing strategies for companies of early to middle stage drug assets to advance their therapies to the global markets.

Prior to joining Mocuis, for 15 years Mr. Jurado held positions in healthcare, marketing, and finance. Mr. Jurado holds a Bachelor of Science and an MBA, in addition to, a Master’s in Biotechnology from Johns Hopkins University.

Jenny (Seungyun) Jo, MBA

Jenny Jo is the founder and CEO of Biojo Sciences and has a long history of leading companies through multi-national markets. For nine years, Ms. Jo served as the CEO of Mocuis, Co., Ltd, an investment and advisory firm for biopharmaceutical companies which focused on early to middle stage drug assets and companies looking to transition from research to a more focused commercialization strategy. Her roles included establishing strategies across different regulatory territories, global commercialization, partnering, and licensing. During Ms. Jo’s tenure, she was a speaker at the 2015 BIO International Convention on the topic of bringing drugs developed outside of the US, into the US regulatory market. Ms. Jo holds a BA in Business and an MBA, as well as, a Master’s in Biotechnology from Johns Hopkins University.

Kenneth Carter, Ph.D.

Dr. Kenneth Carter brings over 25 years of experience in early and clinical-stage biotechnology companies. Dr. Carter has been Chairman of Seneca Biopharma since 2019. He was CEO & President 2012-2017 at Neximmune, an immuno-oncology company spun out of Johns Hopkins and was involved as a special advisor during their successful $30M fundraise in 2018. Dr. Carter founded Avalon Pharmaceuticals in 1999 and served as CEO for ten years until 2009. During his tenure, Avalon completed an IPO on the NASDAQ and established partnerships with Merck, Novartis, Sanofi-Aventis, and AstraZeneca. Prior to Avalon, Dr. Carter directed the gene mapping initiative at Human Genome Sciences.

Dr. Carter has served on numerous corporate and advisory boards including the National BIO Industry Organization, Antidote Therapeutics, Inc., Iterion Pharmaceuticals and the Maryland BioHealth Initiative (BHI). He is also an adjunct faculty member at John Hopkins University.

Kenneth Carter, Ph.D.

Dr. Kenneth Carter brings over 25 years of experience in early and clinical-stage biotechnology companies. Dr. Carter has been Chairman of Seneca Biopharma since 2019. He was CEO & President 2012-2017 at Neximmune, an immuno-oncology company spun out of Johns Hopkins and was involved as a special advisor during their successful $30M fundraise in 2018. Dr. Carter founded Avalon Pharmaceuticals in 1999 and served as CEO for ten years until 2009. During his tenure, Avalon completed an IPO on the NASDAQ and established partnerships with Merck, Novartis, Sanofi-Aventis, and AstraZeneca. Prior to Avalon, Dr. Carter directed the gene mapping initiative at Human Genome Sciences.

Dr. Carter has served on numerous corporate and advisory boards including the National BIO Industry Organization, Antidote Therapeutics, Inc., Iterion Pharmaceuticals and the Maryland BioHealth Initiative (BHI). He is also an adjunct faculty member at John Hopkins University.

Jenny (Seungyun) Jo, MBA

Jenny Jo is the founder and CEO of Biojo Sciences and has a long history of leading companies through multi-national markets. For nine years, Ms. Jo served as the CEO of Mocuis, Co., Ltd, an investment and advisory firm for biopharmaceutical companies which focused on early to middle stage drug assets and companies looking to transition from research to a more focused commercialization strategy. Her roles included establishing strategies across different regulatory territories, global commercialization, partnering, and licensing. During Ms. Jo’s tenure, she was a speaker at the 2015 BIO International Convention on the topic of bringing drugs developed outside of the US, into the US regulatory market. Ms. Jo holds a BA in Business and an MBA, as well as, a Master’s in Biotechnology from Johns Hopkins University.

Brandon Jurado, MBA

As Senior VP of Operations at Biojo, Brandon Jurado has over 20 years of diversified experience. He recently spent over eight years in the biopharmaceutical industry as the Director of Strategy & Business Development and Manager of Global Business Development at Mocuis, Co., Ltd., a biopharmaceutical advisory and investment firm. Mr. Jurado collaborated with business, scientific, regulatory, and investor teams in developing strategies for companies of early to middle stage drug assets to advance their therapies to the global markets.

Prior to joining Mocuis, for 15 years Mr. Jurado held positions in healthcare, marketing, and finance. Mr. Jurado holds a Bachelor of Science and an MBA, in addition to, a Master’s in Biotechnology from Johns Hopkins University.

Message From Our CEO

Biojo Sciences was established to find important therapies for diseases that meet the needs of patients. For many therapeutic innovations to advance to commercialization, it is essential to find the right ingredients in development and funding strategies. Biojo has extensive capabilities to invest in compelling science and overcome the clinical development hurdles – bringing hope to patients and value to stakeholders.

The foundation of our company is to leverage decades of global experience to build efficient and effective solutions in the biopharmaceutical industry. We have brought oncology therapies, biologics, and many other drugs to commercialization. Our aim is to continuously create a structure that delivers early-stage drugs and emerging platforms to patients in need.

Biojo’s team has learned through the years the keys to improving outcomes: culture and integrity. Our culture is shaped around sound collaboration with our team, partners, and network. This gives us a unique advantage in combining both the science and business perspectives, ensuring goals across disciplines are aligned. We also believe the integrity in good science and business practices will transform innovations into valuable therapies.

We look forward to working with passionate scientific and business partners who want to make a meaningful difference in the medicines of tomorrow.

Thank you,

Jenny (Seungyun) Jo

Founder & CEO